| dbo:abstract |
Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta (US) and Kaftrio (EU), is a fixed-dose combination medication used to treat cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators. It is approved for use in the United States for people aged six years and older who have cystic fibrosis with a F508del mutation or other mutations in the CFTR gene. It is also approved for use in Canada, the European Union and Australia. (en) Elexacaftor/tezacaftor/ivacaftor, vendido bajo el nombre comercial de Trikafta (EE.UU.), Kaftrio (UE), es un medicamento combinado utilizado en pacientes con fibrosis quística con la mutación . Este medicamento está compuesto por , e ivacaftor. Fue aprobado para su uso en Estados Unidos en 2019. Su precio de lista se estima en $311.000 dólares americanos por año. En junio de 2020, el Comité de la Agencia Europea de Medicamentos(EMA) recomendó la aprobación de elexacaftor/tezacaftor/ivacaftor (Kaftrio) para el tratamiento de la fibrosis quística. (es) |
| dbo:alternativeName |
Trikafta, Kaftrio (en) |
| dbo:casNumber |
2398469-65-1 |
| dbo:kegg |
D11700 |
| dbo:license |
dbr:Elexacaftor |
| dbo:medlinePlus |
a619061 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Elexacaftor_tezacafto...tor_mechanism_of_action.png?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/elexacaftor https://druginfo.nlm.nih.gov/drugportal/name/ivacaftor%20and%20tezacaftor |
| dbo:wikiPageID |
62140284 (xsd:integer) |
| dbo:wikiPageLength |
29232 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1124971499 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Saskatchewan dbr:Priority_review dbr:Repaglinide dbr:Rhinitis dbr:Cystic_fibrosis dbr:Cystic_fibrosis_transmembrane_conductance_regulator dbr:Vertex_Pharmaceuticals dbr:Institute_for_Clinical_and_Economic_Review dbr:Rash dbr:Oral_administration dbr:Orphan_drug dbr:Elexacaftor dbr:Phase_3_clinical_testing dbr:Chloride_channel_opener dbr:Statin dbr:Committee_for_Medicinal_Products_for_Human_Use dbr:Pharmaceutical_Benefits_Scheme dbr:Warfarin dbr:Alberta dbc:Orphan_drugs dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbr:Breakthrough_therapy dbr:Diarrhea dbr:Fast_track_(FDA) dbr:Nasal_congestion dbr:Health_Canada dbc:Cystic_fibrosis dbr:Ivacaftor dbc:Breakthrough_therapy dbc:Combination_drugs dbr:Cftr dbr:Tezacaftor dbr:Digoxin dbr:CYP3A dbr:CYP3A4 dbr:Spirometry dbr:Influenza dbr:Nateglinide dbr:Ontario dbr:CYP3A5 dbr:Sinusitis dbr:Pharmac dbr:Rhinorrhea dbr:Fixed-dose_combination dbr:Indicated dbr:Alanine_aminotransferase dbr:Glyburide dbr:File:Complex_of_Ivacaftor_bound_to_CFTR.png dbr:File:Elexacaftor.svg dbr:File:Elexacaftor_tezacaftor_ivacaftor_mechanism_of_action.png dbr:File:Ivacaftor.svg dbr:File:Tezacaftor.svg dbr:File:Trikafta.jpg |
| dbp:atcPrefix |
R07 (en) |
| dbp:atcSuffix |
AX32 (en) |
| dbp:casNumber |
2398469 (xsd:integer) |
| dbp:class |
dbr:Chloride_channel_opener CFTR corrector (en) Cystic fibrosis transmembrane conductance regulator corrector (en) |
| dbp:component |
Elexacaftor (en) Ivacaftor (en) Tezacaftor (en) |
| dbp:dailymedid |
Elexacaftor,_tezacaftor,_and_ivacaftor (en) |
| dbp:kegg |
D11700 (en) |
| dbp:legalAu |
S4 (en) |
| dbp:legalCa |
Rx-only (en) |
| dbp:legalEu |
Rx-only (en) |
| dbp:legalUk |
POM (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:medlineplus |
a619061 (en) |
| dbp:pregnancyAu |
B3 (en) |
| dbp:routesOfAdministration |
dbr:Oral_administration |
| dbp:tradename |
Trikafta, Kaftrio (en) |
| dbp:type |
combo (en) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_dmy_dates dbt:Drugs.com dbt:Other_respiratory_system_products |
| dcterms:subject |
dbc:Orphan_drugs dbc:Cystic_fibrosis dbc:Breakthrough_therapy dbc:Combination_drugs |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:CombinationDrug dbo:Drug |
| rdfs:comment |
Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta (US) and Kaftrio (EU), is a fixed-dose combination medication used to treat cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators. It is approved for use in the United States for people aged six years and older who have cystic fibrosis with a F508del mutation or other mutations in the CFTR gene. It is also approved for use in Canada, the European Union and Australia. (en) Elexacaftor/tezacaftor/ivacaftor, vendido bajo el nombre comercial de Trikafta (EE.UU.), Kaftrio (UE), es un medicamento combinado utilizado en pacientes con fibrosis quística con la mutación . Este medicamento está compuesto por , e ivacaftor. Fue aprobado para su uso en Estados Unidos en 2019. Su precio de lista se estima en $311.000 dólares americanos por año. En junio de 2020, el Comité de la Agencia Europea de Medicamentos(EMA) recomendó la aprobación de elexacaftor/tezacaftor/ivacaftor (Kaftrio) para el tratamiento de la fibrosis quística. (es) |
| rdfs:label |
Elexacaftor/tezacaftor/ivacaftor (es) Elexacaftor/tezacaftor/ivacaftor (en) |
| owl:sameAs |
wikidata:Elexacaftor/tezacaftor/ivacaftor dbpedia-es:Elexacaftor/tezacaftor/ivacaftor https://global.dbpedia.org/id/AoX8Q |
| prov:wasDerivedFrom |
wikipedia-en:Elexacaftor/tezacaftor/ivacaftor?oldid=1124971499&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Ivacaftor.svg wiki-commons:Special:FilePath/Complex_of_Ivacaftor_bound_to_CFTR.png wiki-commons:Special:FilePath/Elexacaftor.svg wiki-commons:Special:FilePath/Elexacaftor_tezacaftor_ivacaftor_mechanism_of_action.png wiki-commons:Special:FilePath/Trikafta.jpg wiki-commons:Special:FilePath/Tezacaftor.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Elexacaftor/tezacaftor/ivacaftor |
| is dbo:wikiPageRedirects of |
dbr:Elexacaftor,_tezacaftor_and_ivacaftor dbr:Elexacaftor_/_tezacaftor_/_ivacaftor dbr:Kaftrio dbr:Elexacaftor/ivacaftor/tezacaftor dbr:Trikafta dbr:Elexacaftor,_ivacaftor_and_tezacaftor |
| is dbo:wikiPageWikiLink of |
dbr:Elexacaftor,_tezacaftor_and_ivacaftor dbr:Elexacaftor_/_tezacaftor_/_ivacaftor dbr:Kaftrio dbr:Paul_Negulescu dbr:Elexacaftor dbr:Elexacaftor/ivacaftor/tezacaftor dbr:Ivacaftor dbr:Peter_Grootenhuis dbr:Trikafta dbr:Elexacaftor,_ivacaftor_and_tezacaftor |
| is foaf:primaryTopic of |
wikipedia-en:Elexacaftor/tezacaftor/ivacaftor |
